Lynparza

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
Yahoo/Reuters
AstraZeneca
Lynparza
ovarian cancer
Europe
Flag link:
ASCO 2019 day one
ASCO 2019 day one
Pharmaforum
ASCO 2019
JNJ
Erleada
AstraZeneca
Merck
Lynparza
prostate cancer
Flag link:
Lynparza on cusp of EU approval for advanced ovarian cancer
Lynparza on cusp of EU approval for advanced ovarian cancer
Pharmaforum
AstraZeneca
Lynparza
Europe
CHMP
ovarian cancer
Flag link:
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
Pharmaforum
AstraZeneca
Merck
Lynparza
BRCA-mutant breast cancer
Europe
breast cancer
Flag link:
Early pancreatic cancer data give Clovis a new path in PARP market
Early pancreatic cancer data give Clovis a new path in PARP market
Biopharma Dive
pancreatic cancer
Clovis Oncology
AstraZeneca
PARP inhibitors
AACR
Rubraca
Lynparza
Flag link:
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
Yahoo/Zacks.com
Myriad Genetics
AstraZeneca
BRACAnalysis CDx
diagnostics
Lynparza
Flag link:
FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
Endpoints
AstraZeneca
Merck
Lynparza
BRCA-mutated ovarian cancer
FDA
Flag link:
FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review
FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review
CP Wire
Lynparza
Merck
AstraZeneca
ovarian cancer
FDA
Flag link:
FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review
Lynparza
Merck
AstraZeneca
ovarian cancer
Flag link:
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
PARP inhibitors
physicians
Zejula
Rubraca
Lynparza
AstraZeneca
Merck
Tesaro
Clovis Oncology
Flag link:
Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch
Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch
Fierce Pharma
AstraZeneca
Merck
Lynparza
PARP inhibitors
BRCA-mutated ovarian cancer
Flag link:
AstraZeneca, Merck’s Lynparza gets FDA ODD for pancreatic cancer
AstraZeneca, Merck’s Lynparza gets FDA ODD for pancreatic cancer
Pharmaceutical Business Review
AstraZeneca
Merck
Lynparza
FDA
pancreatic cancer
orphan drug
Flag link:
Major Expected Events from AstraZeneca’s R&D in H2 2018
Major Expected Events from AstraZeneca’s R&D in H2 2018
Market Realist
AstraZeneca
China
Lynparza
Tagrisso
Imfinzi
Flag link:
PARP inhibitors show promise for treating ALS and other brain disorders
PARP inhibitors show promise for treating ALS and other brain disorders
Fierce Biotech
PARP inhibitors
AstraZeneca
Lynparza
Tesaro
Zejula
ALS
Flag link:
AstraZeneca wins speedy approvals for cancer drugs in Japan
AstraZeneca wins speedy approvals for cancer drugs in Japan
Yahoo/Reuters
AstraZeneca
Japan
Imfinzi
Lynparza
Flag link:
AstraZeneca, Merck eye wider cancer drug use after study success
AstraZeneca, Merck eye wider cancer drug use after study success
Yahoo/Reuters
AstraZeneca
Merck
Lynparza
ovarian cancer
Flag link:
ASCO: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer
ASCO: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer
Fierce Pharma
AstraZeneca
Lynparza
prostate cancer
Flag link:
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
CP Wire
AstraZeneca
Merck
Lynparza
metastatic breast cancer
AACR
Flag link:
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
AstraZeneca
Merck
Lynparza
HER-2 negative breast cancer
breast cancer
Flag link:
Myriad’s breast cancer diagnostic wins approval in Japan
Myriad’s breast cancer diagnostic wins approval in Japan
Drug Delivery Business News
Myriad Genetics
diagnostics
breast cancer
Japan
Bracanalysis Diagnostic System
Lynparza
Flag link:

Pages